Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Is Sarepta Therapeutics Stock a Bad-News Buy?
10:00am, Thursday, 09'th Nov 2023
Sarepta released results of its phase 3 trials last week for Elevidys, which fell short of expectations. The company, however, remains optimistic that a label expansion for its gene therapy remains po
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
09:03am, Wednesday, 08'th Nov 2023
Not all technology companies are the same. In fact, not all chipmakers are the same.
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test
01:59pm, Tuesday, 31'st Oct 2023
Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.
Why Sarepta Therapeutics Stock Is Crashing Today
11:52am, Tuesday, 31'st Oct 2023
Sarepta's DMD drug Elevidys failed to meet the primary endpoint in a phase 3 study. However, the company plans to pursue an expanded label for the drug anyway.
Why Are Stocks Down Today?
10:45am, Tuesday, 31'st Oct 2023
Stocks are down today and investors wondering why have come to the right place as we have an answer to that question! Several factors are weighing on the stock market and keeping shares down today.
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
09:38am, Tuesday, 31'st Oct 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Tuesday after the biopharmaceutical company announced results from a Phase 3 clinical trial. That clinical trial covers the use of ELE
Sarepta shares slump as muscle disorder therapy fails to meet key trial goal
08:50am, Tuesday, 31'st Oct 2023
Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the
Sarepta Stock Sinks on Mixed Gene Therapy Results
08:01am, Tuesday, 31'st Oct 2023
In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met.
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
05:52pm, Monday, 30'th Oct 2023
Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.
Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial
04:11pm, Monday, 30'th Oct 2023
Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company reported after the bell on Monday.
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
08:30am, Wednesday, 25'th Oct 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2023 financial results after the Nasd
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
2 Top Growth Stocks to Buy With $500
10:07am, Thursday, 14'th Sep 2023
Sarepta Therapeutics is successfully developing treatments for a rare and devastating disease. Shopify's recent moves should make it even stronger in the fast-growing e-commerce industry.
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
08:30am, Tuesday, 05'th Sep 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
01:00pm, Wednesday, 23'rd Aug 2023
Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some important challenges that could stunt its growth.
